Plus fréquemment testées dans les pays anglosaxons, les incitations financières aux changements de comportement, comme l’arrêt du tabac ou la perte de poids ont reçu jusque-là des preuves d’efficacité ...

Lipozem: Cellular Swelling When toxins—such as pesticides, preservatives, and other chemicals—enter the body, they can attack ...

The Company’s fourth quarter and full-year 2024 financial and operational results are preliminary and are subject to the completion of the Company’s 2024 audit. Audited full-year 2024 and unaudited ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today ...

PRINCETON, N.J., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for ...

Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, ...

Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability and accessibility, today ...

Craig Swandal, experienced medical device manufacturing executive, joins leadership team ...

- Demande de nouveau médicament expérimental (ou IND, de l’anglais Investigational New Drug) planifiée au 1ᵉ trimestre 2025 pour l’EOS-215, un anticorps monoclonal anti-TREM2 supposé meilleur de sa ...

The Company intends to hold its annual meeting no later than December 31, 2025 in order to regain compliance under the NYSE American Company Guide. Matinas BioPharma is a biopharmaceutical company ...

The stock option is subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an ...